Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1997-2-13
|
pubmed:abstractText |
Glucagon secretion from pancreatic alpha cells is inhibited by insulin from beta cells. Amylin is a partner hormone to insulin cosecreted in response to nutrient stimuli, which, like insulin, inhibits beta-cell secretion. We investigated whether amylin also inhibits alpha-cell secretion of glucagon in response to infused L-arginine. Rat amylin (1.2, 3.6, 12, 36, or 120 pmol/kg/min; calculated plasma concentration, 13, 47, 195, 713, and 2,950 pmol/L, respectively; n = 7, 8, 6, 4, and 7) or saline (n = 23) was infused into anesthetized male Harlan-Sprague-Dawley rats during hyperinsulinemic-euglycemic clamps, which were used to equalize the influences of glucose and insulin on glucagon secretion. Plasma glucose and insulin concentrations and mean arterial pressures were not different between amylin- and saline-treated rats during a 10-minute 2-mmol L-arginine infusion delivered during the clamps. Plasma glucagon measurements taken during and after the arginine challenge showed that compared with saline infusions, amylin administration dose-dependently suppressed the glucagon response to arginine by a maximum of 62% (incremental area under the curve [AUC] 0 to 60 minutes) with a plasma amylin EC50 of 18 pmol/L +/- 0.3 log units. These data indicate that amylin potently inhibits arginine-stimulated glucagon secretion.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amyloid,
http://linkedlifedata.com/resource/pubmed/chemical/Arginine,
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Glucagon,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Islet Amyloid Polypeptide,
http://linkedlifedata.com/resource/pubmed/chemical/Lactates
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0026-0495
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
46
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
67-70
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9005972-Amyloid,
pubmed-meshheading:9005972-Animals,
pubmed-meshheading:9005972-Arginine,
pubmed-meshheading:9005972-Blood Glucose,
pubmed-meshheading:9005972-Blood Pressure,
pubmed-meshheading:9005972-Dose-Response Relationship, Drug,
pubmed-meshheading:9005972-Drug Interactions,
pubmed-meshheading:9005972-Glucagon,
pubmed-meshheading:9005972-Infusions, Intravenous,
pubmed-meshheading:9005972-Insulin,
pubmed-meshheading:9005972-Islet Amyloid Polypeptide,
pubmed-meshheading:9005972-Lactates,
pubmed-meshheading:9005972-Male,
pubmed-meshheading:9005972-Rats,
pubmed-meshheading:9005972-Rats, Sprague-Dawley,
pubmed-meshheading:9005972-Time Factors
|
pubmed:year |
1997
|
pubmed:articleTitle |
Dose-response for glucagonostatic effect of amylin in rats.
|
pubmed:affiliation |
Amylin Pharmaceuticals, San Diego, CA 92121, USA.
|
pubmed:publicationType |
Journal Article
|